| Market Capitalization (Millions $) |
2,452 |
| Shares
Outstanding (Millions) |
33 |
| Employees |
63 |
| Revenues (TTM) (Millions $) |
55 |
| Net Income (TTM) (Millions $) |
-157 |
| Cash Flow (TTM) (Millions $) |
107 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Nektar Therapeutics is a biopharmaceutical company based in San Francisco, California, that specializes in developing innovative drugs and therapies for cancer, chronic pain, and autoimmune diseases. The company was founded in 1990 by a team of scientists and experienced pharmaceutical executives with the goal of improving the lives of patients.
Nektar Therapeutics focuses on creating drug candidates using its proprietary technology platforms: PEGylation, Polymer Conjugation, and Permeation Enhancement. These platforms enable the company to create a wide range of therapeutic molecules with optimized pharmacokinetics and enhanced therapeutic profiles.
The PEGylation platform is based on the modification of drugs with polyethylene glycol (PEG), which prolongs the druges half-life in the body, reduces its toxicity, and improves its efficacy. The Polymer Conjugation platform uses proprietary polymer technologies to enhance the pharmacokinetics of the drugs, allowing for better tissue targeting and drug retention. The Permeation Enhancement platform enhances the bioavailability and efficacy of small molecule drugs.
Nektar Therapeutics has a diverse pipeline of products, ranging from cancer therapies to chronic pain treatments. One of their leading products is Onzeald, also known as etirinotecan pegol, a medication for the treatment of advanced breast cancer. This medication uses the PEGylation platform to improve its pharmacokinetics and has shown promising results in clinical trials.
Other products in Nektar Therapeuticse pipeline include NKTR-214, a cancer immunotherapy, NKTR-358, a therapy for autoimmune diseases, and NKTR-102, a treatment for ovarian cancer. The company also has partnerships with major pharmaceutical companies such as Bristol-Myers Squibb and Takeda Pharmaceuticals, which help to advance and commercialize its drug candidates.
Overall, Nektar Therapeutics is a cutting-edge biopharmaceutical company that specializes in developing innovative therapies that help improve the lives of patients suffering from chronic illnesses. Using its proprietary technology platforms, the company has an impressive pipeline of drug candidates that have the potential to revolutionize the treatment of cancer, chronic pain, and autoimmune diseases.
Company Address: 455 Mission Bay Boulevard South San Francisco 94158 CA
Company Phone Number: 482-5300 Stock Exchange / Ticker: NASDAQ NKTR
|
2.68% 
207.28 %